|
rs2981582
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Five SNPs associated with breast cancer risk predominantly among ER-positive tumors (rs2981582/FGFR2, rs4415084/MRPS30, rs1219648/FGFR2, rs2981579/FGFR2, and rs11200014/FGFR2).
|
22965832 |
2012 |
|
rs2981582
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Homozygous variant genotypes of rs2981582 were strongly related to lymph node negative breast cancer (OR = 3.33, P = 6 × 10(-7)) and the minor allele of rs2981582 was associated with increased risk of ER+ tumors (OR = 1.57, P = 0.02; OR = 2.15, P = 0.001, for heterozygous and homozygous variant genotypes, respectively) and increased risk of distant metastasis development (OR = 2.30, P = 4 × 10(-3); OR = 3.57, P = 6 × 10(-5), for heterozygous and homozygous variant genotypes, respectively) in a dose dependent manner.
|
22910930 |
2012 |
|
rs2981582
|
|
|
0.030 |
GeneticVariation |
BEFREE |
FGFR2 rs1219648 and rs2981582 genotypes were significantly associated with breast cancer in EA only in estrogen receptor-positive (ER+), progesterone receptor-positive (PR+) and HER2/Neu-negative (HER2-) tumors.
|
19028704 |
2009 |
|
rs1219648
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We here studied the association of rs1219648 in FGFR2 and rs1042522 in TP53 and their interaction in development of early onset sporadic breast cancer in Iranian Azeri population to evaluate epistatic effects on the risk of mammary neoplasia.
|
25292094 |
2014 |
|
rs1219648
|
|
|
0.020 |
GeneticVariation |
BEFREE |
FGFR2 rs1219648 and rs2981582 genotypes were significantly associated with breast cancer in EA only in estrogen receptor-positive (ER+), progesterone receptor-positive (PR+) and HER2/Neu-negative (HER2-) tumors.
|
19028704 |
2009 |
|
rs755793
|
|
|
0.010 |
GeneticVariation |
BEFREE |
These findings indicated that the TT genotype and T allele frequencies of rs675436 were associated with an increased risk of EBVaGC, while allele A or G of rs755793 had no effect on the occurrence of EBV-associated tumors in Chinese Han population.
|
29446487 |
2018 |
|
rs121918502
|
|
|
0.010 |
GeneticVariation |
BEFREE |
FGFR3 mutations (p.S249C) were found in 8.5% (6/71) of tumors and were significantly associated with FGFR3 protein overexpression (p < 0.001), and unfavourable clinical outcome (p = 0.001).
|
27669755 |
2016 |
|
rs758829154
|
|
|
0.010 |
GeneticVariation |
BEFREE |
NGS detected 3 activating mutations in ESR1, and 3 hot-spot mutations in PIK3CA, and 3 in TP53 in baseline cfDNA, and the ESR1 p.D538G mutation in 1 matched circulating tumor cell sample. ddPCR analysis was more sensitive than NGS and identified 6 additional baseline cfDNA samples with the ESR1 p.D538G mutation at a frequency of <1%.
|
25979954 |
2015 |
|
rs1057520029
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We identified one somatic heterozygous missense mutation, p.K660N (c.1980G>C), within the tyrosine kinase domain of FGFR2 in tumor tissue of a sporadic breast cancer patient, which is likely mediated by the FGFR2-IIIb isoform.
|
23527311 |
2013 |
|
rs1299249877
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We identified one somatic heterozygous missense mutation, p.K660N (c.1980G>C), within the tyrosine kinase domain of FGFR2 in tumor tissue of a sporadic breast cancer patient, which is likely mediated by the FGFR2-IIIb isoform.
|
23527311 |
2013 |
|
rs148478597
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We identified one somatic heterozygous missense mutation, p.K660N (c.1980G>C), within the tyrosine kinase domain of FGFR2 in tumor tissue of a sporadic breast cancer patient, which is likely mediated by the FGFR2-IIIb isoform.
|
23527311 |
2013 |
|
rs1057519854
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The two most common somatic mutations identified were S252W (in eight tumors) and N550K (in five samples).
|
17525745 |
2007 |
|
rs121913476
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The two most common somatic mutations identified were S252W (in eight tumors) and N550K (in five samples).
|
17525745 |
2007 |
|
rs79184941
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The two most common somatic mutations identified were S252W (in eight tumors) and N550K (in five samples).
|
17525745 |
2007 |